244
Views
37
CrossRef citations to date
0
Altmetric
Research Article

Value of 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma

, &
Pages 737-742 | Received 01 Jul 2012, Accepted 31 Aug 2012, Published online: 28 Sep 2012

References

  • Kumar R, Maillard I, Schuster SJ, . Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am 2004;42:1083–1100.
  • Cheng G, Servaes S, Alavi A, . FDG PET and PET/CT in the management of pediatric lymphoma patients. PET Clin 2008;3: 621–634.
  • Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008;111:504–516.
  • Moskowitz CH, Zelenetz A, Schoder H. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. J Natl Compr Canc Netw 2010;8:347–352.
  • Shankar A, Fiumara F, Pinkerton R. Role of FDG PET in the management of childhood lymphomas—case proven or is the jury still out?Eur J Cancer 2008;44:663–673.
  • Cheng G, Alavi A, Zhuang H. Clinical application of FDG PET/CT in pediatric lymphoma patients. PET Clin 2012;7:47–56.
  • Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005;35:165–175.
  • Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007;110:3507–3516.
  • Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am 2008;46:199–211.
  • Montravers F, McNamara D, Landman-Parker J, . [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002;29:1155–1165.
  • Hermann S, Wormanns D, Pixberg M, . Staging in childhood lymphoma: differences between FDG-PET and CT. Nucl Med 2005; 44:1–7.
  • Hernandez-Pampaloni M, Takalkar A, Yu JQ, . F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol 2006;36:524–531.
  • London K, Cross S, Onikul E, . 18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging. Eur J Nucl Med Mol Imaging 2011;38:274–284.
  • Purz S, Mauz-Korholz C, Korholz D, . [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 2011;29:3523–3528.
  • Cheng G, Chen W, Chamroonrat W, . Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging 2011;38:1469–1476.
  • Cheng G, Servaes S, Chamroonrat W, . Non-Hodgkin's lymphoma of the bone and the liver without lymphadenopathy revealed on FDG-PET/CT. Clin Imaging 2010;34:476–479.
  • Ribrag V, Vanel D, Leboulleux S, . Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy. Eur J Radiol 2008;66:325–331.
  • Moulin-Romsee G, Hindié E, Cuenca X, . 18F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 2010;37:1095–1105.
  • Kabickova E, Sumerauer D, Cumlivska E, . Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging 2006;33:1025–1031.
  • Goethals I, Hoste P, De Vriendt C, . Time-dependent changes in 18F-FDG activity in the thymus and bone marrow following combination chemotherapy in paediatric patients with lymphoma. Eur J Nucl Med Mol Imaging 2010;37:462–467.
  • Sugawara Y, Fisher SJ, Zasadny KR, . Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16:173–180.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.